- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Jason Rhodes, Alnylam
I've always loved the life sciences, and have been fortunate to have my career take place during a time of profound advances in biology.
Jason Rhodes
Vice President, Business Development, Alnylam
(JOHN HALPERN)
I've always loved the life sciences, and have been fortunate to have my career take place during a time of profound advances in biology. My first project was a Phase III trial acceleration strategy for what was then Sandoz, now Novartis. That experience provided me with invaluable exposure to many of the central elements of the pharma industry, and gave me a keen appreciation of the challenge of meeting patients' needs in a demanding regulatory environment. The common thread throughout my career has been identifying and realizing new business opportunities based on novel science and technology, and translating new science into successful business opportunities for the benefit of patients and shareholders.
When I joined Alnylam, my daily activities actually became relatively more hands-on compared to my venture capital role. Alnylam's business strategy is to enable the industry to practice RNAi through creative partnerships with a long-term orientation. These partnerships are highly symbiotic with our own product pipeline and business. We use the Greek word for innovation, "kainotomia," to describe our culture and approach, and we are innovative in every aspect of what we do, from science through business. I'm looking forward to continuing to play a role as a leader at Alnylam as we realize the tremendous potential of RNAi in areas such as stem cells, vaccines, bioprocessing, and other applications. It's tremendously gratifying—and a lot of fun—to be part of it.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.
The Transformative Role of Medical Information in Customer Engagement
October 3rd 2024Stacey Fung, Head of Global Medical Information at Gilead Lifesciences, delves into the evolving role of Medical Information (MI) in the pharmaceutical industry. Covering key topics like patient engagement through omnichannel strategies, combating misinformation, and leveraging AI to enhance medical inquiries, the conversation with Stacey highlights MI's critical role in ensuring patient safety and supporting drug development. She also shares her professional journey and tidbits for early career professionals on professional development.
To Tackle the Plastic Waste Crisis in Pharma, Here’s Where to Start
October 30th 2024By demonstrating big advancements in recycling, pharma companies will be much more likely to attract shareholders and other investors, giving themselves a leg up in the competition to lead the biopharmaceutical industry well into the future.
